Viyash's Italian pet-care bid jumps 28% to ₹188 cr
The final price for BioForLife is ₹41 crore above the figure Viyash disclosed earlier this year. The deal remains small against the company's own scale.
— 3 earlier stories on Viyash Scientific Ltd. →What's new
- Viyash signed a binding agreement to acquire Italian pet-care distributor BioForLife for ₹188 crore.
- The price is 28% higher than the ₹147 crore Viyash disclosed for the same target earlier this year.
- BioForLife supplies products to over 80% of Italian veterinary clinics. Viyash plans to use the network to launch Alivira pipeline products.
Why this matters
The ₹41 crore price jump is the story. Viyash's prior disclosure set an expectation; the binding agreement exceeds it without explanation. The strategic logic is consistent with past guidance, but the gap between numbers will need clarity.
What we're watching
- Any clarification on why the binding price is ₹41 crore above the initial disclosure.
- Post-close integration of Alivira products into BioForLife's Italian distribution network.
- How Viyash's capital allocation is perceived after this internal-accruals deal.
The full read
Viyash Scientific's final bid for BioForLife Italia is ₹188 crore. That is 28% more than the ₹147 crore it told the market earlier. The gap is unexplained. The company will fund the deal from internal accruals and expects it to close in Q2 FY27. BioForLife's value is its reach: it supplies nutritional supplements, pharmaceuticals, and diagnostics to more than 80% of Italian veterinary clinics. Viyash plans to launch its Alivira products through that network. The strategic logic is straightforward. The price increase is not. The prior disclosure set a benchmark the final agreement has now cleared, and the difference of ₹41 crore demands a rationale beyond the shift from a preliminary to a binding figure. The deal is small, at just 1.7% of Viyash's market cap, but the price move is a governance question.
Questions answered
- Why is the deal price 28% higher than what Viyash initially disclosed?
- The prior figure of ₹147 crore was disclosed before the agreement became binding. The new ₹188 crore price reflects the final terms. The filing does not state a reason for the increase.
- How significant is this acquisition for Viyash?
- The ₹188 crore price is modest. It represents about 1.7% of Viyash's market capitalisation and an estimated 2.4% revenue impact, falling below mid-cap materiality thresholds.
- What is the strategic purpose of buying BioForLife?
- BioForLife is a distributor that reaches over 80% of Italian veterinary clinics. Viyash plans to use this established network to launch products from its Alivira animal-health pipeline into Europe.
- When will the deal close?
- Viyash expects the acquisition to close in the second quarter of fiscal 2027.
Story so far
All notes on VIYASH →- 8 Jun 2026 · 12:46 PM IST Viyash's Italian pet-care bid jumps 28% to ₹188 cr
- today Viyash buys Italian vet distributor for €17M
- 17d ago Viyash Scientific posts record quarter, sets ₹800 cr EBITDA run-rate for FY27
- 18d ago Viyash Scientific targets ₹1,000 cr EBITDA in 2-3 years, pivots to companion animals